2030 Insurance Coverage and Processing Vaccines 
Express Pharma
MAY 7, 2024
The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.
Express Pharma
JANUARY 12, 2024
Initiatives such as Ayushmaan Bharat Digital Mission (“ADBDM”), CoWIN (a digital vaccine delivery platform), health registry, and telemedicine, highlight the government’s strong emphasis on digitisation of health in India. million nurses/midwives in the total stock by 2030. A recent WHO report estimated a shortage of about 1.8
Expert insights. Personalized for you.
104 
Let's personalize your content